BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15310772)

  • 1. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
    van Roosmalen MS; Stalmeier PF; Verhoef LC; Hoekstra-Weebers JE; Oosterwijk JC; Hoogerbrugge N; Moog U; van Daal WA
    J Clin Oncol; 2004 Aug; 22(16):3293-301. PubMed ID: 15310772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
    Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
    Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
    Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
    Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
    J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
    McQuirter M; Castiglia LL; Loiselle CG; Wong N
    Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
    van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
    J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
    Esplen MJ; Hunter J; Leszcz M; Warner E; Narod S; Metcalfe K; Glendon G; Butler K; Liede A; Young MA; Kieffer S; DiProspero L; Irwin E; Wong J
    Cancer; 2004 Nov; 101(10):2327-40. PubMed ID: 15478194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
    Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
    Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychological distress and quality of life associated with genetic testing for breast cancer risk.
    Smith AW; Dougall AL; Posluszny DM; Somers TJ; Rubinstein WS; Baum A
    Psychooncology; 2008 Aug; 17(8):767-73. PubMed ID: 17992698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M; Gauthier G; Maunsell E; Dugas MJ; Rouleau I; Chiquette J; Plante M; Laframboise R; Gaudet M; Bridge PJ; Simard J
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared decision-making reduces drug use and psychiatric severity in substance-dependent patients.
    Joosten EA; de Jong CA; de Weert-van Oene GH; Sensky T; van der Staak CP
    Psychother Psychosom; 2009; 78(4):245-53. PubMed ID: 19468259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
    J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.
    Mancini J; Noguès C; Adenis C; Berthet P; Bonadona V; Chompret A; Coupier I; Eisinger F; Fricker JP; Gauthier-Villars M; Lasset C; Lortholary A; N'Guyen TD; Vennin P; Sobol H; Stoppa-Lyonnet D; Julian-Reynier C
    Eur J Cancer; 2006 May; 42(7):871-81. PubMed ID: 16563745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations.
    Armstrong K; Weber B; Ubel PA; Peters N; Holmes J; Schwartz JS
    J Clin Oncol; 2005 Dec; 23(36):9319-28. PubMed ID: 16361631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.